Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
3.9
Journals
Biomedicines
Special Issues
State-of-the-Art Hepatic and Gastrointestinal Diseases in Germany
share announcement

State-of-the-Art Hepatic and Gastrointestinal Diseases in Germany

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".

Deadline for manuscript submissions: 31 March 2025 | Viewed by 1636

Special Issue Editor

Prof. Dr. Christa Büchler

E-Mail Website
Guest Editor
Department of Internal Medicine I, University Hospital Regensburg, Regensburg, Germany
Interests: adipose tissue; obesity; non-alcoholic fatty liver disease; adiponectin; chemerin
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Hepatic and gastrointestinal diseases are a broad category of conditions that affect the digestive system and the liver. Inflammatory bowel disease, irritable bowel syndrome, gastro-oesophageal reflux, celiac disease, and liver diseases, such as fatty liver disease, primary sclerosing cholangitis, and hepatocellular carcinoma, are caused by a variety of pathomechanisms that are not yet fully understood. The development of diagnostic tools, therapies, and interventions for the wide range of liver and gastrointestinal diseases requires an understanding of the cellular and molecular mechanisms. The discovery of non-invasive biomarkers for early diagnosis and prognosis is another challenge. We continue to learn more about the mechanisms underlying liver and gastrointestinal diseases thanks to developments in molecular and cellular biology, which are also driving innovation in medical research and healthcare. Pathomechanisms, diagnostics, and treatment aspects of liver and gastrointestinal diseases in Germany are the main topics of this Special Issue. Manuscripts on other topics related to liver and gastrointestinal diseases not covered here will also be considered. Studies on the course of the various diseases and on their prevalence and trends over the last few years in Germany are also very welcome. We invite original research and review articles on all novel aspects of the diagnosis and treatment of hepatic and gastrointestinal diseases in Germany.

Prof. Dr. Christa Büchler
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • biomarker
  • prevalence
  • Germany
  • inflammatory bowel disease
  • cancer

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

13 pages, 7297 KiB  
Article
Stereotactic Percutaneous Electrochemotherapy as a New Minimal Invasive Treatment Modality for Primary and Secondary Liver Malignancies
by Lukas Luerken, Andrea Goetz, Vinzenz Mayr, Liang Zhang, Alexandra Schlitt, Michael Haimerl, Christian Stroszczynski, Hans-Jürgen Schlitt, Matthias Grube, Arne Kandulski and Ingo Einspieler
Biomedicines 2024, 12(12), 2870; https://doi.org/10.3390/biomedicines12122870 - 17 Dec 2024
Viewed by 606
Abstract
Background and Objectives: To report on the first results of safety, efficacy, and outcome of CT-navigated stereotactic percutaneous electrochemotherapy (SpECT) in patients with primary and secondary liver malignancies. Methods: This retrospective study included 23 consecutive lesions in 22 patients who underwent [...] Read more.
Background and Objectives: To report on the first results of safety, efficacy, and outcome of CT-navigated stereotactic percutaneous electrochemotherapy (SpECT) in patients with primary and secondary liver malignancies. Methods: This retrospective study included 23 consecutive lesions in 22 patients who underwent SpECT for primary and secondary malignant liver lesions with locally curative intention. The endpoints were primary technique efficacy (PTE), local tumor progression (LTP), time to progression (TTP), and occurrence of adverse events. Results: The mean maximum diameter of the treated lesions was 42 mm (range: 16 mm–72 mm). Eight lesions were hepatocellular carcinoma (34.8%), five lesions were colorectal liver metastases (21.7%), three lesions were cholangiocellular carcinoma (13.0%), and the other seven lesions were liver metastases from different primary cancers (30.4%). PTE was achieved for 22 lesions (95.7%). The mean follow-up time was 15 months (0–39 months). No LTP was observed. In six patients (27.3%), hepatic tumor progression was observed during follow-up with a mean TTP of 3.8 months (2–8 months). In 10 procedures (43.5%), minor complications (1 CIRSE Grade 2) and side effects occurred, but no major complications were observed. Conclusions: SpECT seems to be a safe and effective new local treatment modality for primary and secondary liver malignancies. Full article
(This article belongs to the Special Issue State-of-the-Art Hepatic and Gastrointestinal Diseases in Germany)
►▼ Show Figures

Figure 1

12 pages, 1831 KiB  
Article
Fecal Nervonic Acid as a Biomarker for Diagnosing and Monitoring Inflammatory Bowel Disease
by Claudia Kunst, Tanja Elger, Johanna Loibl, Muriel Huss, Arne Kandulski, Sabrina Krautbauer, Martina Müller, Gerhard Liebisch, Hauke Christian Tews and Christa Buechler
Biomedicines 2024, 12(12), 2764; https://doi.org/10.3390/biomedicines12122764 - 4 Dec 2024
Viewed by 733
Abstract
Background/Objectives: Inflammatory bowel disease (IBD) is a chronic immune-mediated pathology associated with the dysregulation of lipid metabolism. The administration of nervonic acid, a very long-chain fatty acid, has been shown to improve colonic inflammation in a mouse model of colitis. Our study aimed [...] Read more.
Background/Objectives: Inflammatory bowel disease (IBD) is a chronic immune-mediated pathology associated with the dysregulation of lipid metabolism. The administration of nervonic acid, a very long-chain fatty acid, has been shown to improve colonic inflammation in a mouse model of colitis. Our study aimed to quantify fecal levels of nervonic acid, as well as the very long-chain fatty acids, lignoceric acid, and pentacosanoic acid, to identify associations with IBD activity. Methods: Stool samples were collected from 62 patients with IBD and 17 healthy controls. Nervonic acid, lignoceric acid, and pentacosanoic acid were quantified by gas chromatography coupled with mass spectrometry (GC-MS). Lipid levels, normalized to the dry weight of fecal homogenates, were used for calculations. Results: Patients with IBD exhibited elevated fecal nervonic acid levels compared to healthy controls, with no significant differences observed between ulcerative colitis and Crohn’s disease. A fecal nervonic acid concentration of 0.49 µmol/g distinguished IBD patients from controls, achieving a sensitivity of 71% and a specificity of 82%. Fecal nervonic acid levels showed a positive correlation with both C-reactive protein and fecal calprotectin and increased proportionally with rising fecal calprotectin levels. IBD patients treated with corticosteroids or interleukin-12/23 antibodies had higher levels of fecal nervonic acid than those in other therapies, with no difference in serum C-reactive protein and calprotectin levels between these groups. Conclusions: In summary, this analysis indicates that fecal nervonic acid may emerge as a novel specific biomarker for IBD diagnosis and disease monitoring. Full article
(This article belongs to the Special Issue State-of-the-Art Hepatic and Gastrointestinal Diseases in Germany)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop